NP49119 Hepatitis C Medicines

A Modification Notice
by NHS NATIONAL SERVICES SCOTLAND

Source
Find a Tender
Type
Contract (Goods)
Duration
34 month
Value
£34M
Sector
HEALTH
Published
04 Mar 2022
Delivery
01 Jun 2019 to 31 Mar 2022
Deadline
n/a

Concepts

Location

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014

Geochart for 1 buyers and 3 suppliers

1 buyer

3 suppliers

Description

Total Quantity or Scope

This Framework Agreement is for the supply of medicines used in the treatment of Hepatitis C to NHSScotland. It includes both a treatment cost per medicine and a treatment spend cap.

Award Detail

1 Abbvie (Maidenhead)
  • NP49119 Hepatitis C Medicines
  • Reference: 005998-2022-np49119-1
  • Value: £33,800,000 [share]
  • Awarded to group of suppliers.
2 Gilead Sciences (London)
  • NP49119 Hepatitis C Medicines
  • Reference: 005998-2022-np49119-1
  • Value: £33,800,000 [share]
  • Awarded to group of suppliers.
3 Merck Sharp & Dohme (Hoddesdon)
  • NP49119 Hepatitis C Medicines
  • Reference: 005998-2022-np49119-1
  • Value: £33,800,000 [share]
  • Awarded to group of suppliers.

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated value referred to in Section V.2.4 covers the twenty two (22) months initial duration and the twelve (12)-month extension period. (SC Ref:685674)

Reference

Domains